MEDICE Repositions Itself

Part of the vision of the two MEDICE shareholders and the remaining Schaper & Brümmer shareholders is to develop the traditional company into one of the leading phyto-manufacturers in Europe in association with MEDICE.

In order to consistently implement this vision, MEDICE is pleased to welcome a prominent new member. With Dr. Uwe Baumann, MEDICE has succeeded in bringing a renowned expert in the field of herbal medicines on board, in line with the new acquisition of the majority shares from Schaper&Brümmer. After many years with Hoffmann-La Roche and Novartis, Uwe Baumann has made a decisive contribution to the success of Bionorica over the last 17 years as Chief Executive Officer Global Business at Bionorica. Uwe Baumann joins MEDICE as Managing Director and will be responsible for OTC/OTX (global).

Dr. Jürgen Kreimeyer, who was previously responsible for the German OTC/OTX sector will now take over the new business area "Corporate Communications and Strategic Development" and, together with the shareholders, will steer MEDICE's transformation from a pharmaceutical company to a much broader-based healthcare company. The main focus will be on creating synergies with MediVentures (based in Munich) and Sustainable4U (based in Iserlohn); two companies recently founded by the MEDICE shareholders. At MediVentures, with which he has played a key role in establishing over the past two years, Kreimeyer will be responsible in particular for the area of "Strategic Cooperations". In addition to systematically investing in innovative healthcare startups, MediVentures is specifically advancing the development of digital health applications (DiGA) in close cooperation with eyelevel GmbH, a Munich-based specialist. In addition, Kreimeyer will continue to contribute his long-standing marketing expertise to MEDICE and closely accompany the expansion of Schaper & Brümmer towards a leading, internationally-operating phytopharmaceutical manufacturer.

Nils Wolcke was unanimously confirmed in his position as Managing Director of Schaper&Brümmer and will help drive the joint expansion of the phytopharmaceuticals division.

There are also new developments at MEDICE in the area of prescription drugs. Karsten Sternberg, another experienced manager, moves up in the management of MEDICE. In the future, Sternberg will be globally responsible for the business area with prescription drugs (Rx), apart from the nephrology range. Prior to joining MEDICE, Sternberg was Managing Director of Norgine in Germany and held international marketing and sales positions.

MEDICE is already the undisputed market leader in Europe for ADHD indication with a broad product portfolio*, and the Iserlohn-based family company's plans for further Rx developments are no less ambitious. The product pipeline is said to be well filled.

Eric Neyret will continue to be responsible for MEDICE's CFO function as commercial director. Eric Neyret has already been with MEDICE for 10 years and has made a decisive contribution to the success of the company, in particular by shaping the further development of national and international structures. In addition to the efficient and reliable financial management of the group, Neyret is responsible for the IT area and thus manages the digital transformation in the company. It has already been about two years ago now that he also took over the management of sustainable4U, a company specializing in sustainable nutrition concepts and waste management.

MEDICE has been growing continuously for more than 10 years. The annual turnover of the group of companies is now more than 300 million euros.

*Based on sales in standard units, IQVIA Q4/2024